Latham Secures Unconditional CMA Approval for Coopervision's Acquisition of Sauflon

CMA approves combination of two leading suppliers of contact lenses.

January 16, 2015

On 16 January 2015, the UK Competition and Markets Authority (CMA) published its decision unconditionally approving the acquisition of Sauflon Pharmaceuticals Limited by CooperVision (UK) Holdings, Ltd.

Following detailed submissions by the parties, the CMA concluded that the transaction did not result in a realistic prospect of a significant lessening of competition in the UK.

Latham advised CooperVision on the clearance with a London team led by antitrust partner Omar Shah and including partners John Kallaugher and John Colahan and associates Robert Hardy and Calum Warren, as well as competition economists Compass Lexecon led by Neil Dryden. Latham advised CooperVision on the acquisition in July last year, with a team led by London partner Graeme Ward and corporate associates Andrew Clark and Warren Fernandez.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.